Nalaganje...
Enhancing venetoclax activity in hematological malignancies
INTRODUCTION: Targeting anti-apoptotic pathways involving the BCL2 family proteins represents a novel treatment strategy in hematologic malignancies. Venetoclax, a selective BCL2 inhibitor, represents the first approved agent of this class, and is currently used in CLL and AML. However, monotherapy...
Shranjeno v:
| izdano v: | Expert Opin Investig Drugs |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2020
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7529910/ https://ncbi.nlm.nih.gov/pubmed/32600066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2020.1789588 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|